EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokoll

Risk-stratified breast cancer screening – a protocol for a non-blinded randomised trial

Line Hjøllund Pedersen, Janne Bigaard, Pia Rørbæk Kamstrup, Berit Andersen, Ilse Vejborg, Antonis C Antoniou, Stig Egil Bojesen

Danish Medical Journal · 2025

DOI: 10.61409/a03250154 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Danish Medical Journal, 2025. Verfasst von Line Hjøllund Pedersen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Prevention and Information, Danish Cancer Society. Hauptthemen laut MEDLINE: Breast Neoplasms, Early Detection of Cancer, Mammography, Mass Screening. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION. Breast cancer accounts for 14% of all cancer-related deaths among women. Women aged 50-69 years are offered biennial mammography, which reduces breast cancer-specific mortality. Simulations suggest that risk-stratified screening detects more early-stage cancers while lowering the number of unnecessary recalls, assessments and biopsies in low-risk women. This trial will investigate whether multifactorial risk-stratified screening, including polygenic score, is feasible, acceptable, cost-efficient and safe. METHODS. A minimum of 962 consenting women aged 50-67 years will be randomised 1:1 into a control group receiving standard screening or an intervention group offered screening intervals based on individual risk. Risk factor data collection, communication and follow-up will occur online using a tool co-designed with women in the target group. The primary outcome will be the proportion of low-risk women who, within 800 days of their baseline mammogram, will refrain from their legally ensured two-year mammogram interval. Secondary outcomes include quality of life, anxiety and breast cancer worry, measured at baseline and repeated three times during follow-up. In addition, health economy analyses will be conducted. CONCLUSIONS. The findings will inform the development of large-scale risk-stratified screening trials. FUNDING. Novo Nordisk Foundation, grant no. NNF21OC0070842. ACA is supported by Cancer Research UK grants: PPRPGM-Nov20\100002 and SEBCD3-2024/100001. TRIAL REGISTRATION. ClinicalTrials.gov Identifier: NCT06060938. Registration date: 11092023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEarly Detection of CancerMammographyMass ScreeningHumansFemaleMiddle AgedAgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsQuality of Life

Autor:innen und Institutionen

  • Prevention and Information, Danish Cancer Society.
  • Cancer Survivorship, Danish Cancer Institute, Danish Cancer Society.
  • Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte Hospital.
  • Department of Clinical Medicine, University of Copenhagen.
  • UNICCA - University Research Clinic for Cancer Screening, Department of Public Health Programs, Randers Hospital.
  • Department of Clinical Medicine, University of Aarhus.

Zitieren

APA

Pedersen, L. H., Bigaard, J., Kamstrup, P. R., Andersen, B., Vejborg, I., Antoniou, A. C., & Bojesen, S. E. (2025). Risk-stratified breast cancer screening – a protocol for a non-blinded randomised trial. Danish Medical Journal. https://doi.org/10.61409/a03250154

Vancouver

Pedersen LH, Bigaard J, Kamstrup PR, Andersen B, Vejborg I, Antoniou AC, et al. Risk-stratified breast cancer screening – a protocol for a non-blinded randomised trial. Danish Medical Journal. 2025. doi:10.61409/a03250154

BibTeX
@article{Pedersen2025,
  author = {Pedersen, Line Hjøllund and Bigaard, Janne and Kamstrup, Pia Rørbæk and Andersen, Berit and Vejborg, Ilse and Antoniou, Antonis C and Bojesen, Stig Egil},
  title = {Risk-stratified breast cancer screening – a protocol for a non-blinded randomised trial},
  journal = {Danish Medical Journal},
  year = {2025},
  doi = {10.61409/a03250154}
}
Kostenlos starten →